NCT03247712 - Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

February 13, 2020

Study Completion Date

December 31, 2026

Conditions

Head and Neck CancerHead and Neck Squamous Cell Carcinoma

Interventions

DRUG

Nivolumab

Nivolumab 240mg IV q2wks or 480mg IV q4wks

PROCEDURE

Surgical Resection

Surgical Resection of Tumor

RADIATION

Radiation (5 days)

8Gy x 5 (Mon-Fri) GTV+3mm

RADIATION

Radiation (3 days)

8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm

Trial Locations (1)

Providence Portland Medical Center, Portland

All Listed Sponsors

collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

lead

Providence Health & Services

OTHER